205 related articles for article (PubMed ID: 21912642)
1. Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis.
Badr G; Lefevre EA; Mohany M
PLoS One; 2011; 6(9):e23741. PubMed ID: 21912642
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45.
Fernandis AZ; Cherla RP; Ganju RK
J Biol Chem; 2003 Mar; 278(11):9536-43. PubMed ID: 12519755
[TBL] [Abstract][Full Text] [Related]
3. Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression.
Badr G; Mohany M; Abu-Tarboush F
Lipids Health Dis; 2011 Dec; 10():236. PubMed ID: 22177381
[TBL] [Abstract][Full Text] [Related]
4. Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types.
Badr G; Al-Sadoon MK; Abdel-Maksoud MA; Rabah DM; El-Toni AM
PLoS One; 2012; 7(12):e51661. PubMed ID: 23251606
[TBL] [Abstract][Full Text] [Related]
5. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
[TBL] [Abstract][Full Text] [Related]
6. SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB.
Rehman AO; Wang CY
J Biol Chem; 2008 Jul; 283(29):19888-94. PubMed ID: 18448428
[TBL] [Abstract][Full Text] [Related]
7. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells.
Delgado-Martín C; Escribano C; Pablos JL; Riol-Blanco L; Rodríguez-Fernández JL
J Biol Chem; 2011 Oct; 286(43):37222-36. PubMed ID: 21878648
[TBL] [Abstract][Full Text] [Related]
8. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
9. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
10. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
[TBL] [Abstract][Full Text] [Related]
11. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia.
Ho TK; Tsui J; Xu S; Leoni P; Abraham DJ; Baker DM
J Vasc Surg; 2010 Mar; 51(3):689-99. PubMed ID: 20206813
[TBL] [Abstract][Full Text] [Related]
13. CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation.
Giegold O; Ogrissek N; Richter C; Schröder M; Herrero San Juan M; Pfeilschifter JM; Radeke HH
J Immunol; 2013 Apr; 190(7):3696-705. PubMed ID: 23447686
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.
Shen X; Artinyan A; Jackson D; Thomas RM; Lowy AM; Kim J
Pancreas; 2010 Jan; 39(1):81-7. PubMed ID: 19820417
[TBL] [Abstract][Full Text] [Related]
15. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis.
Fukuda S; Broxmeyer HE; Pelus LM
Blood; 2005 Apr; 105(8):3117-26. PubMed ID: 15618475
[TBL] [Abstract][Full Text] [Related]
16. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton CJ; Wilson JL; Scott K; Stamp G; Wilbanks GD; Fricker S; Bridger G; Balkwill FR
Cancer Res; 2002 Oct; 62(20):5930-8. PubMed ID: 12384559
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone-induced reactive oxygen species causes apoptosis of chondrocytes via PI3K/Akt and p38kinase pathway.
Yu SM; Kim SJ
Exp Biol Med (Maywood); 2013 Jul; 238(7):811-20. PubMed ID: 23788172
[TBL] [Abstract][Full Text] [Related]
19. The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways.
Luo DH; Chen QY; Liu H; Xu LH; Zhang HZ; Zhang L; Tang LQ; Mo HY; Huang PY; Guo X; Mai HQ
J Transl Med; 2013 Aug; 11():203. PubMed ID: 23987636
[TBL] [Abstract][Full Text] [Related]
20. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
